|
|
Friday-Sunday, February 28 – March 2, 2025, Miami, Florida
Fourth Annual National General Medical Oncology SummitA Multitumor CME/MOC-, NCPD- and ACPE-Accredited Educational Conference Developed in Partnership with Florida Cancer Specialists & Research Institute
Dates
Friday to Sunday February 28 to March 2, 2025 Location Fontainebleau Miami Beach 4441 Collins Ave Miami Beach, Florida Hotel Phone: (305) 535-3283 or toll free (800) 548-8886 Meeting Room Coastal Convention Center (Connected to the hotel by a skybridge)
Room Reservations
A special discounted room rate of $399 (plus applicable tax and discounted resort fee) is available to conference attendees at Fontainebleau Miami Beach. Please see the Location tab for details. Note from the Moderator This coming February 28th marks the return of our annual National General Medical Oncology Summit. To add community perspectives, we are pleased to be partnering again with Florida Cancer Specialists & Research Institute for this one-of-a-kind offering that will span 3 days and feature a stellar multidisciplinary faculty panel of clinical investigators and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. The conference’s educational design and the topics that will be discussed offer interested clinicians access to the in-depth perspectives of some of the top minds in the field regarding significant new datasets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with cancer. We hope you will join us in sunny South Florida for a learning experience unlike any other out there. FACULTY Biliary Tract Cancers Mitesh J Borad, MD Professor of Medicine Mayo Clinic College of Medicine and Science Program Leader, Gene and Virus Therapy Program Mayo Clinic Comprehensive Cancer Center Director, Precision Cancer Therapeutics Cancer Program Mayo Clinic Center for Individualized Medicine Scottsdale, Arizona James J Harding, MD Assistant Attending Memorial Sloan Kettering Cancer Center Assistant Professor of Medicine Weill Cornell Medical College New York, New York Breast Cancer Aditya Bardia, MD, MPH Professor of Medicine Geffen School of Medicine at UCLA Director, Breast Oncology Program Assistant Chief (Translational Research) Division of Medical Oncology Director of Translational Research Integration UCLA Health Jonsson Comprehensive Cancer Center Los Angeles, California Virginia F Borges, MD, MMSc Professor of Medicine with Tenure Robert F and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer Research Deputy Head, Division of Medical Oncology Director, Breast Cancer Research Program and Young Women’s Breast Cancer Translational Program University of Colorado Cancer Center Aurora, Colorado Harold J Burstein, MD, PhD Institute Physician Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Boston, Massachusetts Additional faculty to be announced. Chronic Lymphocytic Leukemia Nicole Lamanna, MD Judy Horrigan Professor of Medicine Director of the Chronic Lymphocytic Leukemia Program Leukemia Service, Hematologic Malignancies Section Herbert Irving Comprehensive Cancer Center NewYork-Presbyterian/Columbia University Irving Medical Center New York, New York Kerry A Rogers, MD Associate Professor Division of Hematology The Ohio State University Columbus, Ohio Colorectal Cancer Christopher Lieu, MD Professor of Medicine Associate Director for Clinical Research Co-Director, GI Medical Oncology University of Colorado Cancer Center Aurora, Colorado Kanwal Raghav, MD Associate Professor Gastrointestinal Medical Oncology Executive Medical Director (EMD) Ambulatory Treatment Centers The University of Texas MD Anderson Cancer Center Houston, Texas Gastric Cancer Yelena Y Janjigian, MD Chief of Gastrointestinal Oncology Service Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Zev Wainberg, MD, MSc Co-Director, GI Oncology Program Director of Early Phase Clinical Research Jonsson Comprehensive Cancer Center UCLA School of Medicine Los Angeles, California Gynecologic Cancers David M O'Malley, MD Director and Professor Division of Gynecologic Oncology in Obstetrics and Gynecology John G Boutselis Chair in Gynecologic Oncology The Ohio State University and The James Comprehensive Cancer Center Columbus, Ohio Additional faculty to be announced. Hepatocellular Carcinoma Thomas A Abrams, MD Institute Physician Dana-Farber Cancer Institute Assistant Professor of Medicine Harvard Medical School Director, Liver Tumor Center Boston, Massachusetts Ahmed Omar Kaseb, MD, CMQ John E and Dorothy J Harris Professor in Gastrointestinal Cancer Research Member, National Hepatobiliary Task Force NCI, USA Tenured Professor and Director, Hepatocellular Carcinoma Program Director, MD Anderson HCC SPORE Editor-in-Chief, Journal of Hepatocellular Carcinoma Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Lung Cancer (EGFR Mutation-Positive Non-Small Cell Lung Cancer) Jonathan W Goldman, MD Associate Professor UCLA Hematology and Oncology Director of Clinical Trials in Thoracic Oncology UCLA Health Santa Monica, California Natasha B Leighl, MD, MMSc (Clin Epi) Professor, Department of Medicine Adjunct Professor, IHPME, Dalla Lana School of Public Health University of Toronto OSI Pharmaceuticals Foundation Chair in New Cancer Drug Development Thoracic Oncology Lead, Division of Medical Oncology Princess Margaret Cancer Center Toronto, Ontario Lung Cancer (Immunotherapy and Other Nontargeted Approaches) Stephen V Liu, MD Associate Professor of Medicine Georgetown University Hospital Washington, DC Additional faculty to be announced. Multiple Myeloma Thomas Martin, MD Associate Chief, Hematology/Oncology Director, Hematology, Blood and Marrow Transplantation and Cell Therapy Helen Diller Family Comprehensive Cancer Center UCSF Medical Center San Francisco, California Additional faculty to be announced. Neuroendocrine Tumors Jonathan Strosberg, MD Professor, Dept of GI Oncology Moffitt Cancer Center Tampa, Florida Additional faculty to be announced. Non-Hodgkin Lymphoma Christopher Flowers, MD, MS Division Head, Division of Cancer Medicine Chair, Professor, Department of Lymphoma/Myeloma John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas Additional faculty to be announced. Prostate Cancer Rahul Aggarwal, MD Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research Director, Genitourinary Medical Oncology University of California, San Francisco Department of Medicine Division of Hematology/Oncology Associate Director for Clinical Research UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California William K Oh, MD Clinical Professor of Medicine Division of Hematology and Medical Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, New York MODERATOR Neil Love, MD Research To Practice Miami, Florida Friday to Sunday, February 28 – March 2, 2025 A detailed agenda and speaker information will be made available in the coming months. Times and schedule are subject to change. Preliminary Agenda
Target Audience CE Credit FACULTY — Dr Aggarwal, Dr Burstein, Dr Leighl and Dr Lieu have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Abrams — Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, HistoSonics; Consulting Agreement: Elevar Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP. Dr Bardia — Consulting Agreements and Contracted Research: Alyssum Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Sanofi. Dr Goldman — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Gritstone bio, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Advaxis Inc,AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, Spectrum Pharmaceuticals Inc, Vaccinex Inc. Dr Harding — Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Jazz Pharmaceuticals Inc, Merck, RayzeBio, Servier Pharmaceuticals LLC, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Codiak BioSciences, Jazz Pharmaceuticals Inc, Kinnate Biopharma, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Zymeworks Inc; Data and Safety Monitoring Board/Committee: Merck. Dr Kaseb — Advisory Committees, Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc. Dr Lamanna — Advisory Committees: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Lilly, MingSight Pharmaceuticals, Octapharma, Oncternal Therapeutics. Dr Liu — Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Merus, Mirati Therapeutics Inc, Novartis, OSE Immunotherapeutics, Pfizer Inc, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Revolution Medicines, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, Elevation Oncology, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma Biotechnology Inc, RAPT Therapeutics, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: Candel Therapeutics. Dr Martin — Consulting Agreements: GSK, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Johnson & Johnson Pharmaceuticals, Sanofi; Data and Safety Monitoring Board/Committee: Lilly. Dr O'Malley — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, GSK, Merck, MSD, OncoC4, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Verastem Inc; Contracted Research: AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, OncoC4, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG. Dr Raghav — Advisory Committees and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP,Daiichi Sankyo Inc, Eisai Inc, Guardant Health, Janssen Biotech Inc, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Pfizer Inc. Dr Rogers — Advisory Committees: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, Alpine Immune Sciences, BeiGene Ltd, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis. Dr Wainberg — Consulting Agreements: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Seagen Inc; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Compass Therapeutics, Pfizer Inc. Additional faculty to be announced.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME/NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters Fontainebleau Miami Beach Meeting Room Room Reservations Parking
Map
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.
In-Person Registration Fees This event is free of charge for practicing physicians, fellows, pharmacists, nurses and other healthcare providers actively caring for patients with cancer. For all other individuals, including industry professionals,* a conference registration fee of $1,150 is available through January 31, 2025 and then $1,400 after that day. All fees processed will be nonrefundable after 11:59 PM eastern time on January 31, 2025. To cancel your registration, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (305) 377-2828 or toll free at (800) 233-6153. * Individuals employed by for-profit organizations, including financial institutions and biotech or pharmaceutical companies. Please note, the conference registration fee includes access to book accommodations within the conference block at the discounted rate and access to all conference educational sessions and meal events. If you are interested in exhibiting, please email us at Meetings@ResearchToPractice.com. There is no fee to attend the session virtually. IN-PERSON Registration for clinicians in practice/healthcare professionals (Complimentary)
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » There is no registration fee for clinicians in practice. IN-PERSON Registration for other/industry professionals*
I am not a clinician treating patients. IN-PERSON Registrationfor nonclinicians » Please note, a limited number of seats are available to other/industry professionals.
* Individuals employed by for-profit organizations, including financial institutions and biotech or pharmaceutical companies.
LIVE WEBCAST Registration for all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Meal service will be provided to those who attend the program. Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. |